Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00777920 · ClinicalTrials.gov registry record · Phase 3
Study of Ambrisentan in Participants With Pulmonary Hypertension
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT00777920 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 140 participants.
The verdict
NCT00777920, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
The primary objective of this study is to monitor the long-term safety of ambrisentan in adult participants with pulmonary hypertension. The available ambrisentan doses for this study are 2.5, 5, or 10 mg administered orally once daily. Investigators will be able to adjust ambrisentan dose as clinically indicated. A minimum of 4 weeks between dose adjustments is required. Participants receiving other therapies for pulmonary hypertension that are not contraindicated for concomitant use with ambrisentan are permitted to enroll in this study and continue to receive such therapies. Participants enrolled in this study will receive treatment with ambrisentan until such time as the investigator or participant chooses to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor stops the study.
Interventions
- DRUG Ambrisentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2008-11-17 |
| Est. Completion | 2019-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00777920
The ClinicalTrials.gov registry entry for NCT00777920 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ambrisentan is the first listed.
NCT00777920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00777920 about?
NCT00777920 is a clinical study titled "Study of Ambrisentan in Participants With Pulmonary Hypertension". The primary objective of this study is to monitor the long-term safety of ambrisentan in adult participants with pulmonary hypertension. The available ambrisentan doses for this study are 2.5, 5, or 10 mg administered orally once daily. Investigators will be able to adjust ambrisentan dose as clinic...
What is the current status of trial NCT00777920?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2008-11-17. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT00777920?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT00777920?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.